Irritable bowel syndrome: vizsgálatok itt: Németország
6 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- No phaseTaking peopleStress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients
- Where
- Bamberg
- Életkor
- 18 év to 75 év
- People
- 118
- Run by
- Universität Duisburg-Essen
See details and how to joinNCT06145022 - 2. fázisTaking peopleA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
- Where
- Berlin, Dachau, Hamburg, Karlsruhe, Leipzig, Offenbach
- Életkor
- 18 év to 75 év
- People
- 531 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07545759 · EU 2025-524973-17-00 - 4. fázisTaking peopleControlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)
- Where
- Berlin, Frankfurt am Main, Goch, Hamburg, Hannover, Jerichow, Karlsruhe, Schwerin
- Életkor
- 18 év and over
- People
- 268
- Run by
- REPHA GmbH Biologische Arzneimittel
See details and how to join2024-514892-16-00 - 4. fázisTaking peopleControlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D)
- Where
- Bamberg, Berlin, Bochum, Frankfurt am Main, Hanover, Karlsruhe, Leipzig, Reinfeld
- Életkor
- 18 év and over
- People
- 220
- Run by
- REPHA GmbH Biologische Arzneimittel
See details and how to join2024-514383-61-00 - 4. fázisNot yet taking people in NémetországAmara-Tropfen vs. placebo for irritable bowel syndrome (IBS)
- Where
- Böhlen, Essen, Frankfurt, Goch, Hamburg, Jerichow, Münster, Wallerfing
- Életkor
- 18 év and over
- People
- 106
- Run by
- Weleda AG
See details and how to join2026-526668-19-00 - 4. fázisTaking peopleRandomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)
- Where
- Ahrensburg, Bamberg, Berlin, Böhlen, Brandenburg an der Havel, Dresden, Essen, Frankfurt Am Main, Fulda, Gera, Gladbeck, Goch, Hamburg, Hanover, Heidelberg, Jerichow, Karlsruhe, Köthen, Leipzig, Naunhof, Nürnberg, Offenbach, Reinfeld, Schwerin, Stuttgart, Wiesbaden
- Életkor
- 18 év and over
- People
- 422
- Run by
- SymbioPharm GmbH
See details and how to join2024-512104-19-00